Last Updated: June 25, 2026

Patent: 7,713,930

✉ Email this page to a colleague

Summary for Patent: 7,713,930

Error:Operation timed out after 1001 milliseconds with 0 bytes received

Title:	Acidic insulin preparations having improved stability
Abstract:	The invention relates to a pharmaceutical formulation comprising a polypeptide selected from the group consisting of insulin, an insulin metabolite, an insulin analog, an insulin derivative and combinations thereof; a surfactant or combinations of two or more surfactants; optionally a preservative or combinations of two or more preservatives; and optionally an isotonicizing agent, buffers or further excipients or combinations thereof, the pharmaceutical formulation having a pH in the acidic range.
Inventor(s):	Anette Brunner-Schwarz, Norbert Lill
Assignee:	Sanofi Aventis Deutschland GmbH
Application Number:	US12/328,208
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,713,930
Patent Claims:	see list of patent claims

Details for Patent 7,713,930

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	December 16, 2015	7,713,930	2028-12-04
Eli Lilly And Company	BASAGLAR	insulin glargine	Injection	205692	November 15, 2019	7,713,930	2028-12-04
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	February 25, 2015	7,713,930	2028-12-04
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	March 26, 2018	7,713,930	2028-12-04
Sanofi-aventis U.s. Llc	ADMELOG	insulin lispro	Injection	209196	December 11, 2017	7,713,930	2028-12-04
Sanofi-aventis U.s. Llc	ADMELOG	insulin lispro	Injection	209196	October 19, 2018	7,713,930	2028-12-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,713,930

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Argentina	039688	⤷ Start Trial
Australia	2003238471	⤷ Start Trial
Brazil	0311877	⤷ Start Trial
Brazil	PI0311877	⤷ Start Trial
Canada	2490116	⤷ Start Trial
China	102133393	⤷ Start Trial
China	1662252	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.